AU · rank #1 · 2026-09-08
PGEN
NASDAQ · $2.46B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 3.234 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.48 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 2 |
| Insider signal (90d) $24,662 across 1 unique buyers. | 3.000 |
| Analyst upside Consensus target $14.50 | +104.2% |
| Momentum acceleration 3-month minus 12-month momentum. | +64.85% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 3.75 |
| Gross margin TTM | +53.0% |
| 52w high | $7.72 |
| Market cap (USD) | $2.46B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Precigen is a clinical-stage biotech commercializing PAPZIMEOS for recurrent respiratory papillomatosis while advancing UltraCAR-T and AdenoVerse pipeline assets in oncology.
Rationale
The 104% analyst upside, 100% revision agreement, a 475% earnings surprise, and PAPZIMEOS revenue more than doubling sequentially to $53.1M in Q2 all directly reinforce the analyst_upside strategy's premise that consensus targets are lagging a genuine fundamental inflection.
Material risks
- 1With only 3 analysts covering and a 48% target dispersion, the price target consensus is thin and volatile — a single downgrade or target cut could collapse the apparent upside that drives this screen.
- 2PAPZIMEOS serves a rare-disease niche (RRP), and peak revenue is constrained by a small addressable patient population, meaning the current hypergrowth launch curve will decelerate sharply once the prevalent pool is penetrated.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 3 of 3 voted to proceed.